Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:04:10.626Z.
Calculation as of: 2026-10-06T21:04:10.626Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 148236961db35e193d1d700acaf87b22991c3a1a7f0bfa22e817431605aef681
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Zhengye Biotechnology Holding Limited
Market Cap
$52.60M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.99M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$53.70M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$51.19M
EV/EBITDA Ratio
N/A
TTM Avg
0.76x
3Y Avg
0.97x
5Y Avg
0.97x
Market Cap
$51.12M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$54.14M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zhengye Biotechnology Holding Limited (ZYBT) | $52.60M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $51.88M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Tenax Therapeutics, Inc. (TENX)vs › | $51.19M | N/A | 0.76x | 0.97x | 0.97x |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $54.14M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 9.02x | 5.34x | 6.36x | 5.55x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
